Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges

References

• King AM, Underwood BO, McCahon D, Newman JW, Brown F. Biochemical identification of viruses causing the 1981 outbreaks of foot and mouth disease in the UK. Nature 293(5832), 479–480 (1981).
   PubMed Web of Science ®Google Scholar
• Beck E, Strohmaier K. Subtyping of European foot-and-mouth disease virus strains by nucleotide sequence determination. J. Virol. 61(5), 1621–1629 (1987).
   PubMed Web of Science ®Google Scholar
• Patil PK, Suryanarayana V, Bist P, Bayry J, Natarajan C. Integrity of GH-loop of foot-and-mouth disease virus during virus inactivation: detection by epitope specific antibodies. Vaccine 20(7–8), 1163–1168 (2002).
   PubMedGoogle Scholar
• Cham BE, Vickery K, Tohidi-Esfahani R, Cossart Y. Delipidation of a hepadnavirus: Viral inactivation and vaccine development. J. Virol. Methods 137(1), 160–163 (2006).
   PubMedGoogle Scholar
• Niedrig M, Gregersen JP, Fultz PN, Bröker M, Mehdi S, Hilfenhaus J. Immune response of chimpanzees after immunization with the inactivated whole immunodeficiency virus (HIV-1), three different adjuvants and challenge. Vaccine 11(1), 67–74 (1993).
   PubMedGoogle Scholar
• Jahrling PB, Stephenson EH. Protective efficacies of live attenuated and formaldehyde-inactivated Venezuelan equine encephalitis virus vaccines against aerosol challenge in hamsters. J. Clin. Microbiol. 19(3), 429–431 (1984).
   PubMed Web of Science ®Google Scholar
• Kistner O, Barrett N, Brühmann A et al. The preclinical testing of a formaldehyde inactivated Ross River virus vaccine designed for use in humans. Vaccine 25(25), 4845–4852 (2007).
   PubMed Web of Science ®Google Scholar
• Samina I, Khinich Y, Simanov M, Malkinson M. An inactivated West Nile virus vaccine for domestic geese-efficacy study and a summary of 4 years of field application. Vaccine 23(41), 4955–4958 (2005).
   PubMed Web of Science ®Google Scholar
• Putnak R, Barvir DA, Burrous JM et al. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J. Infect. Dis. 174(6), 1176–1184 (1996).
   PubMed Web of Science ®Google Scholar
• Skinner GR, Davies J. Efficacy of an inactivated vaccine for equine herpesvirus type 1 in a novel hamster model. Intervirology 43(1), 27–35 (2000).
   PubMedGoogle Scholar
• Bell JA, Sundberg JP, Ghim SJ, Newsome J, Jenson AB, Schlegel R. A formalin-inactivated vaccine protects against mucosal papillomavirus infection: a canine model. Pathobiology 62(4), 194–198 (1994).
   PubMed Web of Science ®Google Scholar
• Choi Y, Ahn CJ, Seong KM, Jung MY, Ahn BY. Inactivated Hantaan virus vaccine derived from suspension culture of Vero cells. Vaccine 21(17–18), 1867–1873 (2003).
   PubMed Web of Science ®Google Scholar
• Bahgat MM, Kutkat MA, Nasraa MH et al. Characterization of an avian influenza virus H5N1 Egyptian isolate. J. Virol. Methods 159(2), 244–250 (2009).
   PubMedGoogle Scholar
• Furesz J, Scheifele DW, Palkonyay L. Safety and effectiveness of the new inactivated hepatitis A virus vaccine. CMAJ 152(3), 343–348 (1995).
   PubMed Web of Science ®Google Scholar
• Goncharova E, Ryzhikov E, Poryvaev V et al. Intranasal immunization with inactivated tick-borne encephalitis virus and the antigenic peptide 89–119 protects mice against intraperitoneal challenge. Int. J. Med. Microbiol. 296(Suppl. 40), 195–201 (2006).
   PubMed Web of Science ®Google Scholar
• Heinz F, Holtzmann H, Essl A, Kundt M. [Analysis of the efficiency of tick-borne encephalitis vaccination in the population in the natural foci of Austria]. Vopr. Virusol. 53(2), 19–27 (2008).
   PubMedGoogle Scholar
• Appaiahgari MB, Vrati S. Immunogenicity and protective efficacy in mice of a formaldehyde-inactivated Indian strain of Japanese encephalitis virus grown in Vero cells. Vaccine 22(27–28), 3669–3675 (2004).
   PubMed Web of Science ®Google Scholar
• Alderson T. The mechanism of formaldehyde-induced mutagenesis. The monohydroxymethlyation reaction of formaldehyde with adenylic acid as the necessary and sufficient condition for the mediation of the mutagenic activity of formaldehyde. Mutat. Res. 106, 77–85 (1964).
   PubMedGoogle Scholar
• Progress in the nucleic acid research and molecular biology. Davidson JN (Ed.). Academic Press, New York, NY (1973).
   Google Scholar
• Fraenkel-Conrat H. Reaction of nucleic acid with formaldehyde. Biochim. Biophys. Acta 15(2), 307–309 (1954).
   PubMedGoogle Scholar
• Fraenkel-Conrat H. Chemical modification of viral ribonucleic acid. I. Alkylating agents. Biochim. Biophys. Acta 49, 169–180 (1961).
   PubMedGoogle Scholar
• Michelson AM, Letters R. Synthesis of nucleotide-aminoacyl anhydrides. Biochim. Biophys. Acta 80, 242–246 (1964).
   PubMedGoogle Scholar
• Metz B, Kersten GF, Hoogerhout P et al. Identification of formaldehyde-induced modifications in proteins: reactions with model peptides. J. Biol. Chem. 279(8), 6235–6243 (2004).
   PubMed Web of Science ®Google Scholar
• Fraenkel-Conrat H, Mecham DK. The reaction of formaldehyde with proteins; demonstration of intermolecular cross-linking by means of osmotic pressure measurements. J. Biol. Chem. 177(1), 477–486 (1949).
   PubMed Web of Science ®Google Scholar
• Kuykendall JR, Bogdanffy MS. Efficiency of DNA-histone crosslinking induced by saturated and unsaturated aldehydes in vitro. Mutat. Res. 283(2), 131–136 (1992).
   PubMed Web of Science ®Google Scholar
• Ma TH, Harris MM. Review of the genotoxicity of formaldehyde. Mutat. Res. 196(1), 37–59 (1988).
   PubMed Web of Science ®Google Scholar
• Permana PA, Snapka RM. Aldehyde-induced protein-DNA crosslinks disrupt specific stages of SV40 DNA replication. Carcinogenesis 15(5), 1031–1036 (1994).
   PubMed Web of Science ®Google Scholar
• Brown F. Review of accidents caused by incomplete inactivation of viruses. Dev. Biol. Stand. 81, 103–107 (1993).
   PubMedGoogle Scholar
• Twomey T, Newman J, Burrage T, Piatti P, Lubroth J, Brown F. Structure and immunogenicity of experimental foot-and-mouth disease and poliomyelitis vaccines. Vaccine 13(16), 1603–1610 (1995).
   PubMedGoogle Scholar
• Darnell ME, Subbarao K, Feinstone SM, Taylor DR. Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV. J. Virol. Methods 121(1), 85–91 (2004).
   PubMed Web of Science ®Google Scholar
• Spruth M, Kistner O, Savidis-Dacho H et al. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses. Vaccine 24(5), 652–661 (2006).
   PubMed Web of Science ®Google Scholar
• Qu D, Zheng B, Yao X et al. Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice. Vaccine 23(7), 924–931 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang CH, Guo ZM, Zheng HY et al. Humoral immune responses in rabbits induced by an experimental inactivated severe acute respiratory syndrome coronavirus vaccine prepared from F69 strain. Chin. Med. J. 117(11), 1625–1629 (2004).
   PubMedGoogle Scholar
• Openshaw PJ, Culley FJ, Olszewska W. Immunopathogenesis of vaccine-enhanced RSV disease. Vaccine 20(Suppl. 1), S27–S31 (2001).
   PubMed Web of Science ®Google Scholar
• Ishizaka ST, Israel ZR, Gettie A et al. Induction of mucosal antibody responses by microsphere-encapsulated formalin-inactivated simian immunodeficiency virus in a male urethral challenge model. Vaccine 17(22), 2817–2825 (1999).
   PubMedGoogle Scholar
• Huisman W, Martina BE, Rimmelzwaan GF, Gruters RA, Osterhaus AD. Vaccine-induced enhancement of viral infections. Vaccine 27(4), 505–512 (2009).
   PubMed Web of Science ®Google Scholar
• Griffin DE, Pan CH, Moss WJ. Measles vaccines. Front. Biosci. 13, 1352–1370 (2008).
   PubMedGoogle Scholar
• Kalina WV, Woolums AR, Berghaus RD, Gershwin LJ. Formalin-inactivated bovine RSV vaccine enhances a Th2 mediated immune response in infected cattle. Vaccine 22(11–12), 1465–1474 (2004).
   PubMed Web of Science ®Google Scholar
• Tano Y, Shimizu H, Martin J, Nishimura Y, Simizu B, Miyamura T. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains. Vaccine 25(41), 7041–7046 (2007).
   PubMed Web of Science ®Google Scholar
• Delputte PL, Meerts P, Costers S, Nauwynck HJ. Effect of virus-specific antibodies on attachment, internalization and infection of porcine reproductive and respiratory syndrome virus in primary macrophages. Vet. Immunol. Immunopathol. 102(3), 179–188 (2004).
   PubMedGoogle Scholar
• Delrue I, Delputte PL, Nauwynck HJ. Assessing the functionality of viral entry-associated domains of porcine reproductive and respiratory syndrome virus during inactivation procedures, a potential tool to optimize inactivated vaccines. Vet. Res. 40(6), 62 (2009).
   PubMedGoogle Scholar
• Rossio JL, Esser MT, Suryanarayana K et al. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J. Virol. 72(10), 7992–8001 (1998).
   PubMed Web of Science ®Google Scholar
• Pollock RV, Carmichael LE. Dog response to inactivated canine parvovirus and feline panleukopenia virus vaccines. Cornell Vet. 72(1), 16–35 (1982).
   PubMedGoogle Scholar
• Embalming Chemistry: Glutaraldehyde Versus Formaldehyde. Bedino JH (Ed.). The Champion Company, Springfield, OH, USA (2003).
   Google Scholar
• Hemminki K, Suni R. Sites of reaction of glutaraldehyde and acetaldehyde with nucleosides. Arch. Toxicol. 55(3), 186–190 (1984).
   PubMed Web of Science ®Google Scholar
• McGucken PV, Woodside W. Studies on the mode of action of glutaraldehyde on Escherichia coli. J. Appl. Bacteriol. 36(3), 419–426 (1973).
   PubMedGoogle Scholar
• Cheung DT, Nimni ME. Mechanism of crosslinking of proteins by glutaraldehyde II. Reaction with monomeric and polymeric collagen. Connect. Tissue Res. 10(2), 201–216 (1982).
   PubMed Web of Science ®Google Scholar
• Richards FM, Knowles JR. Glutaraldehyde as a protein cross-linkage reagent. J. Mol. Biol. 37(1), 231–233 (1968).
   PubMed Web of Science ®Google Scholar
• Advances in Protein Chemistry. Anfinsen CB (Ed.). Academic Press, New York, NY, USA (1970).
   Google Scholar
• Bioconjugate Techiques. Hermanson GT (Ed.). Academic Press, San Diego, CA, USA (2008).
   Google Scholar
• Keles I, Woldehiwet Z, Murray RD. Vaccination with glutaraldehyde-fixed bovine respiratory syncytial virus (BRSV)-infected cells stimulates a better immune response in lambs than vaccination with heat-inactivated cell-free BRSV. Vaccine 16(11–12), 1172–1178 (1998).
   PubMed Web of Science ®Google Scholar
• Cepica A, Beauregard M, Qian B. Fluorescence spectroscopy monitoring of the conformational restraint of formaldehyde- and glutaraldehyde-treated infectious bursal disease virus proteins. Vaccine 16(20), 1957–1961 (1998).
   PubMedGoogle Scholar
• Boukhvalova MS, Prince GA, Blanco JC. The cotton rat model of respiratory viral infections. Biologicals 37(3), 152–159 (2009).
   PubMed Web of Science ®Google Scholar
• Chertova E, Crise BJ, Morcock DR, Bess JW Jr, Henderson LE, Lifson JD. Sites, mechanism of action and lack of reversibility of primate lentivirus inactivation by preferential covalent modification of virion internal proteins. Curr. Mol. Med. 3(3), 265–272 (2003).
   PubMed Web of Science ®Google Scholar
• Wootton SK, Yoo D. Homo-oligomerization of the porcine reproductive and respiratory syndrome virus nucleocapsid protein and the role of disulfide linkages. J. Virol. 77(8), 4546–4557 (2003).
   PubMed Web of Science ®Google Scholar
• Lifson JD, Rossio JL, Piatak M Jr et al. Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins. AIDS Res. Hum. Retroviruses 20(7), 772–787 (2004).
   PubMedGoogle Scholar
• Vagenas P, Williams VG, Piatak M Jr et al. Tonsillar application of AT-2 SIV affords partial protection against rectal challenge with SIVmac239. J. Acquir. Immune Defic. Syndr. 52(4), 433–442 (2009).
   PubMed Web of Science ®Google Scholar
• Perrin P, Morgeaux S. Inactivation of DNA by beta-propiolactone. Biologicals 23(3), 207–211 (1995).
   PubMed Web of Science ®Google Scholar
• Uittenbogaard JP, Zomer B, Hoogerhout P, Metz B. Reactions of beta-propiolactone with nucleobase analogues, nucleosides, and peptides: implications for the inactivation of viruses. J. Biol. Chem. 286(42), 36198–36214 (2011).
   PubMed Web of Science ®Google Scholar
• Larghi OP, Nebel AE. Rabies virus inactivation by binary ethylenimine: new method for inactivated vaccine production. J. Clin. Microbiol. 11(2), 120–122 (1980).
   PubMed Web of Science ®Google Scholar
• Desbat B, Lancelot E, Krell T et al. Effect of the b-propiolactone treatment on the adsorption and fusion of influenza A/Brisbane/59/2007 and A/New Caledonia/20/1999 virus H1N1 on a dimyristoylphosphatidylcholine/ganglioside GM3 mixed phospholipids monolayer at the air-water interface. Langmuir 27(22), 13675–13683 (2011).
   PubMedGoogle Scholar
• Jonges M, Liu WM, van der Vries E et al. Influenza virus inactivation for studies of antigenicity and phenotypic neuraminidase inhibitor resistance profiling. J. Clin. Microbiol. 48(3), 928–940 (2010).
   PubMed Web of Science ®Google Scholar
• Monath TP, Fowler E, Johnson CT et al. An inactivated cell-culture vaccine against yellow fever. N. Engl. J. Med. 364(14), 1326–1333 (2011).
   PubMed Web of Science ®Google Scholar
• Roberts A, Lamirande EW, Vogel L et al. Immunogenicity and protective efficacy in mice and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccine. Viral Immunol. 23(5), 509–519 (2010).
   PubMed Web of Science ®Google Scholar
• Bodewes R, Kreijtz JH, van Amerongen G et al. A single immunization with CoVaccine HT-adjuvanted H5N1 influenza virus vaccine induces protective cellular and humoral immune responses in ferrets. J. Virol. 84(16), 7943–7952 (2010).
   PubMedGoogle Scholar
• Sabchareon A, Lang J, Attanath P et al. A new Vero cell rabies vaccine: results of a comparative trial with human diploid cell rabies vaccine in children. Clin. Infect. Dis. 29(1), 141–149 (1999).
   PubMedGoogle Scholar
• Anderson E, Clouthier S, Shewmaker W, Weighall A, LaPatra S. Inactivated infectious haematopoietic necrosis virus (IHNV) vaccines. J. Fish Dis. 31(10), 729–745 (2008).
   PubMed Web of Science ®Google Scholar
• Warrington RE, Cunliffe HR, Bachrach HL. Derivatives of aziridine as inactivants for foot-and-mouth disease virus vaccines. Am. J. Vet. Res. 34(8), 1087–1091 (1973).
   PubMedGoogle Scholar
• Bahnemann HG. Inactivation of viruses in serum with binary ethyleneimine. J. Clin. Microbiol. 3(2), 209–210 (1976).
   PubMedGoogle Scholar
• Bahnemann HG. Binary ethylenimine as an inactivant for foot-and-mouth disease virus and its application for vaccine production. Arch. Virol. 47(1), 47–56 (1975).
   PubMed Web of Science ®Google Scholar
• Bahnemann HG. Inactivation of viral antigens for vaccine preparation with particular reference to the application of binary ethylenimine. Vaccine 8(4), 299–303 (1990).
   PubMedGoogle Scholar
• Broo K, Wei J, Marshall D et al. Viral capsid mobility: a dynamic conduit for inactivation. Proc. Natl Acad. Sci. USA 98(5), 2274–2277 (2001).
   PubMedGoogle Scholar
• Gates KS, Nooner T, Dutta S. Biologically relevant chemical reactions of N7-alkylguanine residues in DNA. Chem. Res. Toxicol. 17(7), 839–856 (2004).
   PubMed Web of Science ®Google Scholar
• Hendler S, Fürer E, Srinivasan PR. Synthesis and chemical properties of monomers and polymers containing 7-methylguanine and an investigation of their substrate or template properties for bacterial deoxyribonucleic acid or ribonucleic acid polymerases. Biochemistry 9(21), 4141–4153 (1970).
   PubMed Web of Science ®Google Scholar
• Aaskov J, Williams L, Yu S. A candidate Ross River virus vaccine: preclinical evaluation. Vaccine 15(12–13), 1396–1404 (1997).
   PubMed Web of Science ®Google Scholar
• Awad M, Michael A, Soliman SM, Samir SS, Daoud AM. Trials for preparation of inactivated sheep pox vaccine using binary ethyleneimine. Egypt. J. Immunol. 10(2), 67–72 (2003).
   PubMedGoogle Scholar
• Race E, Frezza P, Stephens DM et al. An experimental chemically inactivated HIV-1 vaccine induces antibodies that neutralize homologous and heterologous viruses. Vaccine 13(1), 54–60 (1995).
   PubMedGoogle Scholar
• Berhane Y, Berry JD, Ranadheera C et al. Production and characterization of monoclonal antibodies against binary ethylenimine inactivated Nipah virus. J. Virol. Methods 132(1–2), 59–68 (2006).
   PubMedGoogle Scholar
• Vanhee M, Delputte PL, Delrue I, Geldhof MF, Nauwynck HJ. Development of an experimental inactivated PRRSV vaccine that induces virus-neutralizing antibodies. Vet. Res. 40(6), 63 (2009).
   PubMedGoogle Scholar
• Weismiller DG, Sturman LS, Buchmeier MJ, Fleming JO, Holmes KV. Monoclonal antibodies to the peplomer glycoprotein of coronavirus mouse hepatitis virus identify two subunits and detect a conformational change in the subunit released under mild alkaline conditions. J. Virol. 64(6), 3051–3055 (1990).
   PubMedGoogle Scholar
• Li Y, Breaker RR. Kinetics of RNA degradation by specific base catalysis of transesterification involving the 2´-hydroxyl group. J. Am. Chem. Soc. 121, 5364–5372 (1999).
   Web of Science ®Google Scholar
• Lelie PN, Reesink HW, Lucas CJ. Inactivation of 12 viruses by heating steps applied during manufacture of a hepatitis B vaccine. J. Med. Virol. 23(3), 297–301 (1987).
   PubMedGoogle Scholar
• Schlegel A, Immelmann A, Kempf C. Virus inactivation of plasma-derived proteins by pasteurization in the presence of guanidine hydrochloride. Transfusion 41(3), 382–389 (2001).
   PubMedGoogle Scholar
• Fleming P. Thermal inactivation of Semliki Forest virus. J. Gen. Virol. 13(3), 385–391 (1971).
   PubMedGoogle Scholar
• Dimmock NJ. Differences between the thermal inactivation of picornaviruses at “high” and “low” temperatures. Virology 31(2), 338–353 (1967).
   PubMed Web of Science ®Google Scholar
• Laude H. Thermal inactivation studies of a coronavirus, transmissible gastroenteritis virus. J. Gen. Virol. 56(Pt 2), 235–240 (1981).
   PubMedGoogle Scholar
• Poon B, Safrit JT, McClure H et al. Induction of humoral immune responses following vaccination with envelope-containing, formaldehyde-treated, thermally inactivated human immunodeficiency virus type 1. J. Virol. 79(8), 4927–4935 (2005).
   PubMed Web of Science ®Google Scholar
• Perdiz D, Grof P, Mezzina M, Nikaido O, Moustacchi E, Sage E. Distribution and repair of bipyrimidine photoproducts in solar UV-irradiated mammalian cells. Possible role of Dewar photoproducts in solar mutagenesis. J. Biol. Chem. 275(35), 26732–26742 (2000).
   PubMed Web of Science ®Google Scholar
• Sinha RP, Häder DP. UV-induced DNA damage and repair: a review. Photochem. Photobiol. Sci. 1(4), 225–236 (2002).
   PubMed Web of Science ®Google Scholar
• Miller RL, Plagemann PG. Effect of ultraviolet light on mengovirus: formation of uracil dimers, instability and degradation of capsid, and covalent linkage of protein to viral RNA. J. Virol. 13(3), 729–739 (1974).
   PubMed Web of Science ®Google Scholar
• Sauerbier W, Hercules K. Gene and transcription unit mapping by radiation effects. Annu. Rev. Genet. 12, 329–363 (1978).
   PubMedGoogle Scholar
• Henning J, Meers J, Davies PR. Exposure of rabbits to ultraviolet light-inactivated rabbit haemorrhagic disease virus (RHDV) and subsequent challenge with virulent virus. Epidemiol. Infect. 133(4), 731–735 (2005).
   PubMedGoogle Scholar
• Sarzotti M, Dean TA, Remington M, Hoffman PM. Ultraviolet-light-inactivated Cas-Br-M murine leukemia virus induces a protective CD8+ cytotoxic T lymphocyte response in newborn mice. AIDS Res. Hum. Retroviruses 10(12), 1695–1702 (1994).
   PubMedGoogle Scholar
• Subasinghe HA, Loh PC. Reovirus cytotoxicity: some properties of the UV-irradiated reovirus and its capsid proteins. Arch. Gesamte Virusforsch. 39(1), 172–189 (1972).
   PubMedGoogle Scholar
• Grieb T, Forng RY, Brown R et al. Effective use of gamma irradiation for pathogen inactivation of monoclonal antibody preparations. Biologicals 30(3), 207–216 (2002).
   PubMed Web of Science ®Google Scholar
• Smolko EE, Lombardo JH. Virus inactivation studies using ion beams, electron and gamma irradiation. Nuclear Instrum. Methods Physics Res. Sec. B-Beam Interact. Mater. Atoms 236, 249–253 (2005).
   Google Scholar
• McCormick JB, Mitchell SW, Kiley MP, Ruo S, Fisher-Hoch SP. Inactivated Lassa virus elicits a non protective immune response in rhesus monkeys. J. Med. Virol. 37(1), 1–7 (1992).
   PubMed Web of Science ®Google Scholar
• Di Trani L, Cordioli P, Falcone E et al. Standardization of an inactivated H17N1 avian influenza vaccine and efficacy against A/Chicken/Italy/13474/99 high-pathogenicity virus infection. Avian Dis. 47(Suppl. 3), 1042–1046 (2003).
   PubMed Web of Science ®Google Scholar
• Grovit-Ferbas K, Hsu JF, Ferbas J, Gudeman V, Chen IS. Enhanced binding of antibodies to neutralization epitopes following thermal and chemical inactivation of human immunodeficiency virus type 1. J. Virol. 74(13), 5802–5809 (2000).
   PubMedGoogle Scholar
• Rooijakkers EJ, Uittenbogaard JP, Groen J, Osterhaus AD. Rabies vaccine potency control: comparison of ELISA systems for antigenicity testing. J. Virol. Methods 58(1–2), 111–119 (1996).
   PubMed Web of Science ®Google Scholar
• Fournier-Caruana J, Poirier B, Haond G et al. Inactivated rabies vaccine control and release: use of an ELISA method. Biologicals 31(1), 9–16 (2003).
   PubMed Web of Science ®Google Scholar
• Morgeaux S, Milne C, Daas A. Feasibility study to develop a common in vitro D antigen assay for inactivated poliomyelitis vaccines. Pharmeuropa Bio 2005(1), 19–26 (2005).
   PubMedGoogle Scholar
• Owsianka AM, Tarr AW, Keck ZY et al. Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J. Gen. Virol. 89(Pt 3), 653–659 (2008).
   PubMedGoogle Scholar
• Lee JE, Saphire EO. Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it. Curr. Opin. Struct. Biol. 19(4), 408–417 (2009).
   PubMed Web of Science ®Google Scholar
• Coughlin MM, Babcook J, Prabhakar BS. Human monoclonal antibodies to SARS-coronavirus inhibit infection by different mechanisms. Virology 394(1), 39–46 (2009).
   PubMed Web of Science ®Google Scholar
• Osborne JC Jr, Miller JH, Kempner ES. Molecular mass and volume in radiation target theory. Biophys. J. 78(4), 1698–1702 (2000).
   PubMedGoogle Scholar
• Feron VJ, Til HP, de Vrijer F, Woutersen RA, Cassee FR, van Bladeren PJ. Aldehydes: occurrence, carcinogenic potential, mechanism of action and risk assessment. Mutat. Res. 259(3–4), 363–385 (1991).
   PubMed Web of Science ®Google Scholar